While most biotech startups chase drug discovery, Helomics is playing a different game: they've built a living library of cancer cells and paired it with AI to predict which treatments will actually work. It's a high-stakes, high-reward model that has already attracted over $200M in funding.

"Helomics isn't just storing cancer cells; they're building a predictive engine that treats tumors as data problems to be solved."

Their tech stack—built on jQuery, Tailwind CSS, and Bootstrap—suggests a functional, product-focused approach rather than bleeding-edge frontend frameworks. The real innovation lies in the backend: a proprietary database of patient-derived cancer models and machine learning algorithms designed to match tumors with effective therapies.

• Biobank + AI Fusion: Combines physical cell libraries with predictive analytics
• Patient-Derived Models: Uses actual cancer cells for testing, not just simulations
• Predictive Oncology Focus: Targets treatment personalization over generic solutions
• Regulatory Pathway: Positioned to navigate FDA and clinical trial complexities